Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, dedicated to the discovery and development of innovative cancer therapies. Utilizing its proprietary drug development platforms, Oric targets significant unmet medical needs in oncology, particularly concerning resistance to existing treatments. The company's promising pipeline, which includes candidates designed to inhibit specific mechanisms of cancer cell survival, positions it favorably to advance clinical trials that could transform treatment paradigms for patients facing difficult-to-treat malignancies.